A Close Look at the Data Backing Upadacitinib's Approval in Crohn's

(MedPage Today) -- The selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) improved clinical remission and endoscopic response rates compared with placebo in patients with moderate-to-severe Crohn's disease, according to two induction...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news